First evidence of greater cardiovascular protective effects of newer as compared to old antihypertensive drugs treatments: The ASCOT-BPLA results;Première démonstration d'une supériorité des agents antihypertenseurs modernes par rapport aux molécules plus anciennes dans la prévention cardio-vasculaire: Résultats du bras "abaissement de pression artérielle" de l'étude ASCOT

Revue Medicale de Liege

Volumn 60, Issue 10, 2005, Pages 820-826

  Krzesinski, J M ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

ACE inhibitor; Amlodipine; Antihypertensive treatment; Betablocker; Calcium channel blocker; Coronary heart disease; Diabetes; Diuretic; Hypertension; Perindopril

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATENOLOL; ATORVASTATIN; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; LOSARTAN; PERINDOPRIL; POTASSIUM; STATINE DERIVATIVE; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG USE; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; MORTALITY; OUTCOMES RESEARCH; RISK FACTOR; FEMALE; MALE; MIDDLE AGED;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 28244458434     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Staessen J, Wang J-G, Thijs L.- Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet, 2001, 358, 1305-1315.
2. Chobanian A, Bakris G, Black H, et al.- The JNC 7 Report - The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA, 2003, 289, 2560-2572.
3. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).- Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA, 2002, 288, 2981-2997.
4. Scheen AJ, Krzesmski J-M.- Quel antihypertenseur en première intention? Résultats de l'étude ALLHAT. Rev Med Liège, 2003, 58, 47-52.
5. Dahlöf B, Devereux R, Kjeldsen S, et al.- Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 2002, 359, 995-1003.
6. Blood Pressure Lowering Treatment Trialists' Collaboration.-Effects of different blood-pressure regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet, 2003, 362, 1527-1535.
7. Verdecchia P, Reboldi G, Angeli F, et al.- Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension, 2005, 45, 386-392.
8. Sever P, Dahlöf B, Poulter N, et al.- Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. J Hypertens, 2001, 19, 1139-1147.
9. Sever P, Dahlöf B, Poulter N, et al.- Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, 2003. 361, 1149-1158.
10. Scheen AJ.- Interruption prématurée des études ASCOT et CARDS de prévention cardio-vasculaire avec l'atorvastatine chez le sujet hypertendu ou diabétique: compromis entre éthique et statistique en médecine factuelle. Rev Med Liège, 2003, 58, 585-590.
11. Dahlöf G, Sever P, Poulter N, et al.- Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet, 2005, 366, 895-906.
12. The Prospectives Studies Collaboration.- Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet, 202, 360, 1903-1913.
13. Staessen J, Birkenhäger W.- Evidence that new antihypertensives are superior to older drugs. Lancet, 2005, 366, 869-871.
14. Guidelines Committee.- 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens, 2003, 21, 1011-1053.
15. Krzesinski J-M.- Actualisation de la prise en charge de l'hypertension artérielle. Rev Med Liège, 1999, 54, 683-687.
16. Institut National d'Assurance Maladie-Invalidité. La place des médicaments dans le traitement de l'hypertension. Folia Pharmacotherapeutica, 2001, (suppl.) 11, 3-7.
17. Centre Belge d'Information Pharmacothérapcutique.- Traitement initial de l'hypertension artérielle: état de la question. Folia Pharmacotherapeutica, 2004, 31, 28-32.
18. Collins R. Peto R, MacMahon S, et al.- Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet, 1990, 335, 827-838.
19. Poulter N, Wedel H, Dahlöf B, et al.- Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet, 2005, 366, 907-913.
20. Scheen AJ.- Reduction comparable des nouveaux cas de diabète de type 2 sous sartan et sous inhibiteur de l'enzyme de conversion de l'angiotensine: Comparaison des méta-analyses des essais prospectifs randomisés. Rev Med Liège, 2005, 60, 424-428.